Jun 3, 2019
Anji Pharmaceuticals, Inc. announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR) from Elcelyx Therapeutics. Metformin DR is an investigational product designed to target metformin delivery to the lower small intestine for the treatment of diabetes.
Based in the global pharmaceutical hubs of Cambridge, MA and Shanghai, China, Anji Pharmaceuticals is focused on tackling high-value pharmaceutical targets validated by human genetics. DaHui represented Anji Pharmaceuticals as its sole legal counsel on this acquisition, with the team being led by partner Zheng Zha and counsel Mark Young.